THE new Hadlima (adalimumab) 40mg/0.4mL formulation will be listed on the PBS from 01 Oct.
Organon Australia has launched this high concentration, citrate-free formulation for treating chronic inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
The updated biosimilar reduces the injection volume by 50% and eliminates citrate buffers, known to cause injection-site pain.
Additionally, it can be stored at room temperature for up to 31 days, offering improved convenience for patients.
Hadlima is available in autoinjector and pre-filled syringe formats.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Oct 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Oct 24
